AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
GILD   77.83 (+3.33%)
NFLX   419.73 (+1.52%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
GILD   77.83 (+3.33%)
NFLX   419.73 (+1.52%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
GILD   77.83 (+3.33%)
NFLX   419.73 (+1.52%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
GILD   77.83 (+3.33%)
NFLX   419.73 (+1.52%)
Log in

ASX:CSLCSL Stock Price, Forecast & News

A$307.61
+2.39 (+0.78 %)
(As of 05/12/2020)
Add
Compare
Today's Range
A$302.31
Now: A$307.61
A$308.00
50-Day Range
A$298.76
MA: A$312.55
A$329.00
52-Week Range
A$200.37
Now: A$307.61
A$342.75
Volume869,289 shs
Average Volume900,202 shs
Market Capitalization$139.62 billion
P/E Ratio69.64
Dividend Yield0.97%
BetaN/A
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. It also operates approximately 140 plasma collection centers. In addition, this segment conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and developsinfluenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Read More
CSL logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 2.5Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-3-93891911

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.94 billion
Cash FlowA$1.48 per share
Book ValueA$13.40 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$139.62 billion
Next Earnings DateN/A
OptionableOptionable

Receive CSL News and Ratings via Email

Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter.

CSL (ASX:CSL) Frequently Asked Questions

How has CSL's stock been impacted by COVID-19 (Coronavirus)?

CSL's stock was trading at A$303.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CSL stock has increased by 1.3% and is now trading at A$307.61. View which stocks have been most impacted by Coronavirus.

How were CSL's earnings last quarter?

CSL Limited (ASX:CSL) released its quarterly earnings data on Wednesday, August, 14th. The company reported $4.24 EPS for the quarter, topping analysts' consensus estimates of $4.22 by $0.01. View CSL's earnings history.

How often does CSL pay dividends? What is the dividend yield for CSL?

CSL declared a Interim dividend on Thursday, February 13th. Stockholders of record on Thursday, April 9th will be given a dividend of 1.416 per share on Thursday, April 9th. This represents a yield of 0.43%. The ex-dividend date is Wednesday, March 11th. This is a boost from CSL's previous Interim dividend of A$1.20. View CSL's dividend history.

Has CSL been receiving favorable news coverage?

News stories about CSL stock have trended very negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CSL earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutCSL.

Who are some of CSL's key competitors?

What other stocks do shareholders of CSL own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CSL investors own include BHP Group (BHP), Commonwealth Bank of Australia (CBA), Cochlear (COH), RESMED/IDR UNRESTR (RMD), Woodside Petroleum (WPL), Altium (ALU), Afterpay Touch Group (APT), Appen (APX), REA Group (REA) and Telstra (TLS).

Who are CSL's key executives?

CSL's management team includes the following people:
  • Mr. Paul R. Perreault, MD, CEO & Exec. Director (Age 62)
  • Mr. David Mark Lamont ACA, BCom, Chief Financial Officer (Age 53)
  • Dr. Robert Andrew Cuthbertson, Chief Scientific Officer & Director of R&D and Director (Age 64)
  • Mr. Gregory Boss BS(Hons), J.D., Exec. VP of Legal & Group Gen. Counsel (Age 58)
  • Ms. Elizabeth Walker, Exec. VP & Chief HR Officer (Age 49)

What is CSL's stock symbol?

CSL trades on the ASX under the ticker symbol "CSL."

What is CSL's stock price today?

One share of CSL stock can currently be purchased for approximately A$307.61.

How big of a company is CSL?

CSL has a market capitalization of $139.62 billion and generates $8.94 billion in revenue each year.

What is CSL's official website?

The official website for CSL is www.csl.com.au.

How can I contact CSL?

CSL's mailing address is 45 Poplar Road,, Parkville, MELBOURNE, VIC 3052, Australia. The company can be reached via phone at +61-3-93891911.

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.